Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Is the NHS ready to embrace psychedelics as medicine?; DEA again boosts 2022 production goals for psychedelic medicines; MAPS and Vine Ventures raise US$70m through revenue sharing model
Has psychedelic research reached a tipping point?; Psychedelics can change humanity for the better; Seelos Therapeutics raises US$20m in private placement
Enhancing the accessibility of psychedelic healthcare; MDMA and psychotherapy in combination could be used to treat alcoholism; Psychedelic therapy is poised to revolutionise mental health. Can VR accelerate it?
Inside the UK’s campaign to reschedule psilocybin with MP Crispin Blunt; Awakn signs MOU with the NHS to increase accessibility of psychedelic medicines; DEA once again boosts psilocybin, MDMA and DMT production quotas
Psychedelic Healthcare: The Next Five Years; COMPASS Pathways shares update from Phase IIb clinical trial; Will the magic of psychedelics transform psychiatry?
Will the UK be the first European country to embrace psilocybin-assisted therapy?; COMPASS shares COMP360 open-label study data; Where the psychedelic revolution is headed.
Will the UK be the first European country to embrace psilocybin-assisted therapy?; COMPASS shares COMP360 open-label study data; Where the psychedelic revolution is headed.
Numinus CEO, Payton Nyquvest, on the company’s growth and acquisition strategy; UK PM Boris Johnson to consider latest advice on legalisation of psilocybin; The DEA has proposed a surge in the production of psychedelic medicines.
Small Pharma’s Chief Medical and Scientific Officer, Carol Routledge, on DMT’s power to treat Major Depressive Disorder; atai creates subsidiary to target depression with precision psychiatry; How COVID-19 opened the door to a new era in psychedelic medicine.
The Psychedelics as Medicine Report: Third Edition; Seattle City Council passes resolution to decriminalise psychedelics; 24 hour countdown to PSYCH Investor Summit: Data & Technology
NeonMind’s President and CEO, Robert Tessarolo, on psilocybin’s efficacy in treating obesity; MDMA, LSD and magic mushrooms: are these drugs the future of therapy? CaaMTech raises US$22m in Series A funding round
NeonMind’s President and CEO, Robert Tessarolo, on psilocybin’s efficacy in treating obesity; MDMA, LSD and magic mushrooms: are these drugs the future of therapy? CaaMTech raises US$22m in Series A funding round
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Subscribe to the Psychedelics Newsletter
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
